Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
| ▸ | CYP17A1 | P05093 | 3/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.32 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | CTSA | P10619 | 1/20 | 0.31 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | GCGR | P47871 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18713644 | 0.92 | TRPV1 (0.39) | TRPV1CYP17A1KCNH2FFAR1KCNA3 | |
| SCHEMBL20032350 | 0.88 | PTGS2 (0.34) | KCNH2HTR2ASLC6A4CNR1CYP1A2 | |
| SCHEMBL21366928 | 0.85 | KCNH2 (0.43) | CYP17A1KCNH2KCNA3CNR1GCGR | |
| SCHEMBL20032447 | 0.84 | AKR1C3 (0.39) | GCGR | |
| SCHEMBL18713973 | 0.83 | KCNH2 (0.40) | CYP17A1KCNH2CTSAGCGR | |
| SCHEMBL20032501 | 0.83 | P2RX3 (0.38) | SLC6A4CTSA | |
| SCHEMBL20032375 | 0.83 | TRPV1 (0.36) | TRPV1CNR1 | |
| SCHEMBL20032485 | 0.82 | KCNH2 (0.38) | KCNH2CTSAGCGR | |
| SCHEMBL20032499 | 0.82 | PTGS2 (0.41) | KCNH2 | |
| SCHEMBL20032373 | 0.82 | KCNH2 (0.38) | KCNH2CTSACNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180092918-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | ALTAVANT SCIENCES GMBH (CH) | 2018-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180092918-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | TPH1, TPH2, HTR1A | TRPV1 430/4885CYP17A1 189/4885KCNH2 3159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.